Stereo-selectivity of Enantiomeric Inhibitors to Ubiquitin-specific Protease 7 (USP7) Dissected by Molecular Docking, Molecular Dynamics Simulations, and Binding Free Energy Calculations

Overview

Journal Mol Divers

Date 2024 Sep 19

PMID 39298085

Authors

Yusheng Zhang

Wenwen Dou

Ziqi Zhao

Guozhen Li

Chunlong Li

Xiangyu Chen

Linkai Mou

Affiliations

Soon will be listed here.

Abstract

The ubiquitin-specific protease 7 (USP7), as a member of deubiquitination enzymes, represents an attractive therapeutic target for various cancers, including prostate cancer and liver cancer. The change of the inhibitor stereocenter from the S to R stereochemistry (S-ALM → R-ALM34) markedly improved USP7 inhibitory activity. However, the molecular mechanism for the stereo-selectivity of enantiomeric inhibitors to USP7 is still unclear. In this work, molecular docking, molecular dynamics (MD) simulations, molecular mechanics/Generalized-Born surface area (MM/GBSA) calculations, and free energy landscapes were performed to address this mystery. MD simulations revealed that S-ALM34 showed a high degree of conformational flexibility compared to the R-ALM34 counterpart, and S-ALM34 binding led to the enhanced intradomain motions of USP7, especially the BL1 and BL2 loops and the two helices α4 and α5. MM/GBSA calculations showed that the binding strength of R-ALM34 to USP7 was stronger than that of S-ALM34 by - 4.99 kcal/mol, a similar trend observed by experimental data. MM/GBSA free energy decomposition was further performed to differentiate the ligand-residue spectrum. These analyses not only identified the hotspot residues interacting with R-ALM34, but also revealed that the hydrophobic interactions from F409, K420, H456, and Y514 play the major determinants in the binding of R-ALM34 to USP7. This result is anticipated to shed light on energetic basis and conformational dynamics information to aid in the design of more potent and selective inhibitors targeting USP7.

References

Chen Y, Xue H, Jin J . Applications of protein ubiquitylation and deubiquitylation in drug discovery. J Biol Chem. 2024; 300(5):107264. PMC: 11087986. DOI: 10.1016/j.jbc.2024.107264. View

Huang C, Yang T, Lin K . Mechanisms and functions of SUMOylation in health and disease: a review focusing on immune cells. J Biomed Sci. 2024; 31(1):16. PMC: 10821541. DOI: 10.1186/s12929-024-01003-y. View

Carreira L, Oliveira R, Moreira V, Salvador J . Ubiquitin-specific protease 7 (USP7): an emerging drug target for cancer treatment. Expert Opin Ther Targets. 2023; 27(11):1043-1058. DOI: 10.1080/14728222.2023.2266571. View

Guo N, Wang B, Zhang Y, Kang H, Nie H, Feng M . USP7 as an emerging therapeutic target: A key regulator of protein homeostasis. Int J Biol Macromol. 2024; 263(Pt 1):130309. DOI: 10.1016/j.ijbiomac.2024.130309. View

Hu M, Li P, Li M, Li W, Yao T, Wu J . Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde. Cell. 2003; 111(7):1041-54. DOI: 10.1016/s0092-8674(02)01199-6. View

Korenev G, Yakukhnov S, Druk A, Golovina A, Chasov V, Mirgayazova R . USP7 Inhibitors in Cancer Immunotherapy: Current Status and Perspective. Cancers (Basel). 2022; 14(22). PMC: 9688046. DOI: 10.3390/cancers14225539. View

Park H, Baek K . Current and future directions of USP7 interactome in cancer study. Biochim Biophys Acta Rev Cancer. 2023; 1878(6):188992. DOI: 10.1016/j.bbcan.2023.188992. View

Oliveira R, Guedes R, Salvador J . Highlights in USP7 inhibitors for cancer treatment. Front Chem. 2022; 10:1005727. PMC: 9520255. DOI: 10.3389/fchem.2022.1005727. View

Peng Y, Tang R, Ding L, Zheng R, Liu Y, Yin L . Diosgenin inhibits prostate cancer progression by inducing UHRF1 protein degradation. Eur J Pharmacol. 2023; 942:175522. DOI: 10.1016/j.ejphar.2023.175522. View

10.

Sakamoto T, Kuboki S, Furukawa K, Takayashiki T, Takano S, Yoshizumi A . TRIM27-USP7 complex promotes tumour progression via STAT3 activation in human hepatocellular carcinoma. Liver Int. 2022; 43(1):194-207. DOI: 10.1111/liv.15346. View

11.

Zhang M, Lan X, Li X, Lu S . Pharmacologically targeting intracellular allosteric sites of GPCRs for drug discovery. Drug Discov Today. 2023; 28(12):103803. DOI: 10.1016/j.drudis.2023.103803. View

12.

Zhang M, Chen T, Lu X, Lan X, Chen Z, Lu S . G protein-coupled receptors (GPCRs): advances in structures, mechanisms, and drug discovery. Signal Transduct Target Ther. 2024; 9(1):88. PMC: 11004190. DOI: 10.1038/s41392-024-01803-6. View

13.

Gavory G, ODowd C, Helm M, Flasz J, Arkoudis E, Dossang A . Discovery and characterization of highly potent and selective allosteric USP7 inhibitors. Nat Chem Biol. 2017; 14(2):118-125. DOI: 10.1038/nchembio.2528. View

14.

Morris G, Huey R, Lindstrom W, Sanner M, Belew R, Goodsell D . AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem. 2009; 30(16):2785-91. PMC: 2760638. DOI: 10.1002/jcc.21256. View

15.

Olsson M, Sondergaard C, Rostkowski M, Jensen J . PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKa Predictions. J Chem Theory Comput. 2015; 7(2):525-37. DOI: 10.1021/ct100578z. View

16.

Maier J, Martinez C, Kasavajhala K, Wickstrom L, Hauser K, Simmerling C . ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. J Chem Theory Comput. 2015; 11(8):3696-713. PMC: 4821407. DOI: 10.1021/acs.jctc.5b00255. View

17.

Wang J, Wolf R, Caldwell J, Kollman P, Case D . Development and testing of a general amber force field. J Comput Chem. 2004; 25(9):1157-74. DOI: 10.1002/jcc.20035. View

18.

Wang L, Schauperl M, Mobley D, Bayly C, Gilson M . A Fast, Convenient, Polarizable Electrostatic Model for Molecular Dynamics. J Chem Theory Comput. 2024; 20(3):1293-1305. PMC: 10867846. DOI: 10.1021/acs.jctc.3c01171. View

19.

Roe D, Cheatham 3rd T . PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data. J Chem Theory Comput. 2015; 9(7):3084-95. DOI: 10.1021/ct400341p. View

20.

Wang E, Sun H, Wang J, Wang Z, Liu H, Zhang J . End-Point Binding Free Energy Calculation with MM/PBSA and MM/GBSA: Strategies and Applications in Drug Design. Chem Rev. 2019; 119(16):9478-9508. DOI: 10.1021/acs.chemrev.9b00055. View